Investment Rating - The investment rating for the company is "Buy" (maintained) [2][15] Core Views - The company achieved a revenue of 692 million yuan in 2024, a year-on-year decrease of 11.81%, with a net profit attributable to shareholders of 175 million yuan, down 31.34% [7] - The gross margin for 2024 was 80.72%, a decrease of 2.00 percentage points, while the net margin was 25.26%, down 7.19 percentage points [7] - The company is expected to see growth driven by marketing reforms in provinces outside of Zhejiang, despite short-term sales pressure [7] Financial Performance Summary - Revenue for 2024 was 692 million yuan, with a year-on-year decline of 11.81% [11] - Net profit attributable to shareholders for 2024 was 175 million yuan, down 31.34% [11] - The company forecasts net profits of 208 million yuan, 240 million yuan, and 274 million yuan for 2025, 2026, and 2027 respectively [7][11] - The earnings per share (EPS) are projected to be 1.05 yuan, 1.21 yuan, and 1.38 yuan for 2025, 2026, and 2027 respectively [7][11] Product and Market Analysis - Revenue from Ganoderma lucidum spore powder products decreased by 16.53% to 445 million yuan in 2024 [8] - Revenue from Dendrobium candidum products fell by 11.00% to 113 million yuan [8] - The company plans to enhance its sales model and marketing strategies to expand its market presence outside of Zhejiang [8] Clinical Research and Internationalization - Clinical research on the anti-tumor effects of Ganoderma lucidum spore powder is progressing well, involving 17 top-tier hospitals [9] - The company is collaborating with the Mayo Clinic on research related to cardiovascular disease treatment using its products [9]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The company achieved a revenue of 692 million yuan in 2024, a year-on-year decrease of 11.81%, with a net profit attributable to shareholders of 175 million yuan, down 31.34% [7] - The company is expected to experience growth driven by marketing reforms outside its home province, despite short-term sales pressure [7] - The projected net profits for 2025, 2026, and 2027 are 208 million yuan, 240 million yuan, and 274 million yuan respectively, with corresponding EPS of 1.05 yuan, 1.21 yuan, and 1.38 yuan [7] Financial Performance Summary - In 2024, the gross margin was 80.72%, down 2.00 percentage points, and the net margin was 25.26%, down 7.19 percentage points [7] - The sales expense ratio increased to 43.89%, while the management expense ratio rose to 12.60% [7] - The company’s total revenue is projected to recover to 728 million yuan in 2025, with a growth rate of 5.2% [11] Product and Market Analysis - Revenue from Ganoderma lucidum spore powder products decreased by 16.53% to 445 million yuan, while revenue from Dendrobium candidum products fell by 11.00% to 113 million yuan [8] - The company plans to enhance its sales model and marketing strategies to expand its market presence outside Zhejiang province [8] Clinical Research and Internationalization - Clinical research projects are progressing well, including studies on the anti-tumor effects of Ganoderma lucidum spore powder [9] - The company is collaborating with top medical institutions, such as the Mayo Clinic, to advance the internationalization of its products [9]

【SynBioCon】 获 悉， 近日， 东北林业大学、中国中医科学院中药研究所、浙江寿仙谷医药股份有限公司 等多 家单位联合在中国工程院院刊《 Engineering 》 在线发表了题为 "Unveiling the Spatiotemporal Landscape of Ganoderma lingzhi : Insights into Ganoderic Acid Distribution and Biosynthesis" 的研究论文，通过时 空多组学技术系统解析了灵芝酸的生物合成机制。通过空间质谱成像技术精准绘制了灵芝酸在原基和子实体中的时空 动态分布图谱；完成灵芝 T2T 完整基因组测序并构建了高分辨率单细胞转录组图谱，成功解析了子实体皮壳层的发 育轨迹；发现一个新颖的 CYP450 酶特异性催化生成灵芝酸关键中间体 —— 丹芝酸 E 和 F 。该研究为阐明灵芝 酸复杂的生物合成网络提供了时空多组学研究范式，为开发灵芝酸小分子创新药物和实现资源可持续利用奠定理。 灵芝作为药食两用的 " 仙草 " ，在中医药中已有 2000 多年应用历史。由于其基因组小、生长周期短、遗传体系完 善等特点，灵芝已成为 ...

寿仙谷（603896）公告，2024年营业收入6.92亿元，同比下降11.81%。归属于上市公司股东的净利润 1.75亿元，同比下降31.34%。公司拟以2024年度利润分配股权登记日的总股本为基数，向全体股东每10 股派发现金红利2.7元(含税)。 ...

寿仙谷（603896）公告，公司全资子公司浙江寿仙谷药房连锁有限公司拟以330万元受让浙江寿仙谷投 资管理有限公司所持有的杭州寿仙谷健康药房连锁有限公司100%股权。本次交易完成后，杭州寿仙谷 药房将成为寿仙谷的全资孙公司。此次交易旨在提高资产完整性，进一步整合优质资源，交易对价以现 金方式支付，并已签署相关协议。 ...

Core Viewpoint - The announcement provides an update on the conversion results of the "Shou 22 Convertible Bond" and the changes in the company's share capital as of March 31, 2025, highlighting the low conversion rate and the remaining unconverted bond amount. Group 1: Conversion Status - From May 23, 2023, to March 31, 2025, the total amount converted from the "Shou 22 Convertible Bond" is 309,000 yuan, accounting for 0.0776% of the total issuance [2][5] - The total number of shares formed from the conversion is 8,097 shares, representing 0.0041% of the company's total shares before conversion [2][5] - As of March 31, 2025, the amount of "Shou 22 Convertible Bond" that has not been converted is 397,691,000 yuan, which constitutes 99.92% of the total issuance [2][6] Group 2: Recent Quarter Conversion - In the first quarter of 2025, from January 1 to March 31, the cumulative conversion amount is 1,000 yuan, which is 0.0003% of the total convertible bond issuance [2][5] - The number of shares formed during this period is 26 shares, accounting for 0.00001% of the total shares before conversion [2][5] Group 3: Bond Issuance Overview - The "Shou 22 Convertible Bond" was approved for issuance on November 17, 2022, with a total issuance of 39.8 million yuan, consisting of 398,000 bonds at a face value of 100 yuan each [3] - The bond has a six-year term with a tiered interest rate starting from 0.5% in the first year to 2.5% in the sixth year [3] Group 4: Conversion Price Adjustments - The initial conversion price was set at 38.08 yuan per share, which was adjusted to 37.65 yuan on July 4, 2023, and further adjusted to 37.27 yuan on June 20, 2024, and finally to 37.11 yuan on July 8, 2024, due to various corporate actions [4]

Investment Rating - The industry investment rating is "Positive," indicating an expected overall return exceeding 5% above the CSI 300 index in the next six months [13]. Core Views - The pharmaceutical sector experienced a decline of 0.84% on March 24, 2025, underperforming the CSI 300 index by 1.35 percentage points, ranking 21st among 31 sub-industries [5]. - Notable performances within sub-industries include vaccines (+0.17%) and medical research outsourcing (-0.16%), while hospitals (-2.17%) and medical devices (-1.35%) lagged [5]. - Alnylam's RNAi therapy Vutrisiran has received FDA approval for treating wild-type or hereditary ATTR-CM in adults, aimed at reducing cardiovascular mortality and hospitalizations [6]. Summary by Sections Market Performance - On March 24, 2025, the pharmaceutical sector's performance was -0.84%, underperforming the CSI 300 index by 1.35% [5]. - The top three gainers were Tianyu Co. (+9.95%), Zhongyuan Qihe (+8.82%), and Shanwaishan (+6.60%), while the largest decliners were Aipeng Medical (-10.22%), Innovation Medical (-9.97%), and Sanbo Brain Science (-8.99%) [5]. Industry News - Alnylam announced FDA approval for Vutrisiran, a subcutaneous RNAi therapy targeting specific mRNA to block the production of transthyretin protein, enhancing efficacy and metabolic stability [6]. - Garden Biologics reported a 13.58% year-on-year increase in revenue to 1.243 billion yuan for 2024, with a net profit growth of 60.76% to 309 million yuan [7]. - Shouxiangu reported a 10.87% decline in revenue to 699 million yuan for 2024, with a net profit decrease of 27.87% to 184 million yuan [7].

Group 1: Company Performance - BYD reported a net profit of 40.254 billion yuan for 2024, representing a year-on-year increase of 34% [1] - The company's operating revenue reached 777.102 billion yuan, up 29.02% compared to the previous year [1] - Satellite Chemical achieved a net profit of 6.072 billion yuan in 2024, marking a 26.77% increase year-on-year [2] Group 2: Dividend Proposals - BYD plans to distribute a cash dividend of 39.74 yuan per 10 shares (tax included) [1] - Satellite Chemical intends to distribute a cash dividend of 5 yuan per 10 shares (tax included) [2] Group 3: Stock Market Activity - Junshen Co. is in the preparatory stage for an overseas transshipment project, which has not yet commenced operations [2] - Zhenhua Heavy Industry's stock price increased by 33.58% over a short period, despite no significant changes in its fundamentals [3] - Yuxing Anchor Chain's stock also experienced a significant price increase, with its main business remaining stable [4] Group 4: Strategic Moves - Taihao Technology plans to acquire a 13.87% stake in Jiangxi Taihao Military Group through a share issuance [7] - Dafeng Industrial signed a strategic cooperation agreement with Shanghai Zhiyuan New Technology Co., aiming to explore innovative applications in entertainment and sports [8]

注：1、上表数据以公司未经审计的合并报表数据填列。 二、经营业绩和财务状况情况说明 （一）经营业绩、财务状况及影响经营业绩的主要因素 寿仙谷: 寿仙谷2024年度业绩快报公告 证券代码：603896 证券简称：寿仙谷 公告编号：2025-012 债券代码：113660 债券简称：寿 22 转债 浙江寿仙谷医药股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本公告所载2024年度主要财务数据为初步核算数据，未经会计师事务所审 计，具体数据以浙江寿仙谷医药股份有限公司（以下简称"公司"）2024年年度 报告中披露的数据为准，敬请投资者注意投资风险。 一、2024年度主要财务数据和指标 | | | | 单位：元 币种：人民币 | | | | | --- | --- | --- | --- | --- | --- | --- | | 项 | 目 | 本报告期 | 上年同期 | | | 增减变动幅度（％） | | 营业总收入 | | 699,107,038.17 | 784,347,256.55 | | -10.87 | ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 15% relative to the industry index within the next six months [4][11]. Core Views - The company has shown steady revenue performance in Q3, although profits are slightly under pressure. The revenue for H1 2024 was 350 million yuan, a year-on-year decrease of 5.1%, while the net profit attributable to shareholders was 100 million yuan, an increase of 11.8% year-on-year [1][2]. - The company is experiencing a decline in revenue from major products due to insufficient consumer demand, but the domestic market remains stable. Revenue from key product categories such as Ganoderma lucidum spore powder and Dendrobium officinale has decreased by 6.6% and 6.0% respectively [2]. - The company is actively optimizing its marketing structure and expanding its channels, with the addition of 7 new specialty stores and 14 new channels in the first half of the year. This is expected to enhance product demand in the upcoming peak seasons [2][3]. Financial Summary - For the fiscal year 2022, the company reported a revenue of 829 million yuan, which is projected to decrease to 784 million yuan in 2023, followed by a recovery to 850 million yuan in 2024 [1][5]. - The net profit attributable to shareholders is expected to recover from 254 million yuan in 2023 to 284 million yuan in 2024, with a projected growth rate of 11.7% [1][5]. - The company's gross margin for H1 2024 was 81.3%, a slight decrease of 0.8 percentage points year-on-year, primarily due to reduced scale effects and the impact of new production areas [2][6]. Market and Product Insights - The company’s revenue from the domestic market was 250 million yuan, reflecting a year-on-year growth of 7.4%, while revenue from outside the province and online sales saw significant declines of 24.7% and 26.6% respectively [2]. - The report anticipates stable growth in the traditional Chinese medicine and health products industry, supported by the company's core competitive advantages and ongoing research and innovation efforts [2][3]. Future Projections - The company is expected to achieve net profits of 280 million yuan, 310 million yuan, and 350 million yuan for the years 2024, 2025, and 2026 respectively, with corresponding price-to-earnings ratios of 14, 13, and 11 times [2][3].